Zevra Therapeutics is trading 5.22% higher at $11.29, with no specific catalyst identified. - No company-specific announcement dated October 7, 2026, was found; the investor-relations page lists October 2 as the latest release. - Biotech was down 2.50%, and broader market context was also negative, so those trends do not explain the stock’s gain. - No reliable intraday volume data was found.